Netherlands – Security services – Services related to tabletop exercises in the fields of physical security, crisis management, and business continuity.

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). It is responsible for the scientific evaluation, supervision and safety monitoring of medicines. EMA operates from its Headquarters in Amsterdam, The Netherlands. EMA is evaluating the possibility of launching in the future a tender procedure for the procurement of services related to the planning, organization, and delivery of tabletop exercises in the fields of physical security, crisis management and business continuity. The services would be related to tabletop exercises having as baseline scenarios major security incidents occurring at the EMA premises and/or in the hosting environment (Amsterdam, North Holland, The Netherlands), or any other serious incident or event potentially affecting the normal operations of the Agency or the safety and security of its personnel, assets, information and operations, either in The Netherlands, Europe or Worldwide. Additional information: Preliminary market research: Please note that EMA is running preliminary market research as part of the evaluation process on whether to launch the above-mentioned procurement procedure. The market research is intended to foster EMA’s understanding of services available in the market as well the characteristics of the economic operators delivering said services. Economic operators interested in participating in this preliminary market research are invited to complete the online questionnaire which is available under this link: https://ec.europa.eu/eusurvey/runner/9c914c8c-aa26-f8b6-94d1-baec5caef030 The market research is open for contribution from 24 August 2026 08:00 and the deadline to participate in the online questionnaire is 30 September 2026 at 13.00. Participation in the survey is not a prerequisite to submit a tender if the procurement procedure will be published. Participating to the market research in no case implies a commitment from the European Medicines Agency to procure services to any